DNA vs ALMS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 24, 2026

DNA

51.5
AI Score
VS
ALMS Wins

ALMS

56.8
AI Score

Investment Advisor Scores

DNA

52score
Recommendation
HOLD

ALMS

57score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric DNA ALMS Winner
Revenue 39.63M 3.40M DNA
Net Income -129.30M -235.27M DNA
Net Margin -326.3% -6913.7% DNA
Operating Income -129.92M -247.26M DNA
ROE -30.8% -52.0% DNA
ROA -13.1% -42.0% DNA
Total Assets 990.05M 560.62M DNA
Cash 84.53M 63.71M DNA
Current Ratio 4.57 6.74 ALMS
Free Cash Flow -95.51M -168.98M DNA

Relative Price Performance (Last 90 Days)

DNA 1M: -6.7% · 3M: -8.4% ALMS 1M: -14.6% · 3M: +9.0%

Current Technical Phase

DNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 46.2 · Price: $7.40

ALMS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 42

RSI (14): 42.2 · Price: $24.17

Fundamentals Snapshot

Metric DNA ALMS
Market Cap
Forward P/E -2.6 -8.4
Trailing P/E
Revenue (TTM)
Revenue Growth -0.5% -0.4%
Gross Margin 0.7% 1.0%
Operating Margin -2.8% -64.4%
EPS -5.33 -3.91
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, ALMS is currently the stronger investment candidate, winning 1 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.